The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Neurologic Disorders Therapeutics Market Research Report 2025

Global Neurologic Disorders Therapeutics Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1720708

No of Pages : 71

Synopsis
A neurological disorder is any disorder of the nervous system. Structural, biochemical or electrical abnormalities in the brain, spinal cord or other nerves can result in a range of symptoms. Examples of symptoms include paralysis, muscle weakness, poor coordination, loss of sensation, seizures, confusion, pain and altered levels of consciousness. There are many recognized neurological disorders, some relatively common, but many rare.
The global Neurologic Disorders Therapeutics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Neurologic Disorders Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neurologic Disorders Therapeutics.
Report Scope
The Neurologic Disorders Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Neurologic Disorders Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neurologic Disorders Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Biogen Inc.
F. Hoffmann-La Roche Ltd.
Johnson & Johnson Services Inc.
Novartis AG
Pfizer Inc.
Segment by Type
Central Nervous System (CNS)
Peripheral Nervous System (PNS)
Segment by Application
Paralysis
Muscle Weakness
Poor Coordination
Loss of Sensation
Seizures
Confusion
Pain and Altered Levels of Consciousness
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neurologic Disorders Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neurologic Disorders Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Central Nervous System (CNS)
1.2.3 Peripheral Nervous System (PNS)
1.3 Market by Application
1.3.1 Global Neurologic Disorders Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Paralysis
1.3.3 Muscle Weakness
1.3.4 Poor Coordination
1.3.5 Loss of Sensation
1.3.6 Seizures
1.3.7 Confusion
1.3.8 Pain and Altered Levels of Consciousness
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Neurologic Disorders Therapeutics Market Perspective (2019-2030)
2.2 Neurologic Disorders Therapeutics Growth Trends by Region
2.2.1 Global Neurologic Disorders Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Neurologic Disorders Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Neurologic Disorders Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Neurologic Disorders Therapeutics Market Dynamics
2.3.1 Neurologic Disorders Therapeutics Industry Trends
2.3.2 Neurologic Disorders Therapeutics Market Drivers
2.3.3 Neurologic Disorders Therapeutics Market Challenges
2.3.4 Neurologic Disorders Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neurologic Disorders Therapeutics Players by Revenue
3.1.1 Global Top Neurologic Disorders Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Neurologic Disorders Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Neurologic Disorders Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Neurologic Disorders Therapeutics Revenue
3.4 Global Neurologic Disorders Therapeutics Market Concentration Ratio
3.4.1 Global Neurologic Disorders Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neurologic Disorders Therapeutics Revenue in 2023
3.5 Neurologic Disorders Therapeutics Key Players Head office and Area Served
3.6 Key Players Neurologic Disorders Therapeutics Product Solution and Service
3.7 Date of Enter into Neurologic Disorders Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Neurologic Disorders Therapeutics Breakdown Data by Type
4.1 Global Neurologic Disorders Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Neurologic Disorders Therapeutics Forecasted Market Size by Type (2025-2030)
5 Neurologic Disorders Therapeutics Breakdown Data by Application
5.1 Global Neurologic Disorders Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Neurologic Disorders Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Neurologic Disorders Therapeutics Market Size (2019-2030)
6.2 North America Neurologic Disorders Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Neurologic Disorders Therapeutics Market Size by Country (2019-2024)
6.4 North America Neurologic Disorders Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Neurologic Disorders Therapeutics Market Size (2019-2030)
7.2 Europe Neurologic Disorders Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Neurologic Disorders Therapeutics Market Size by Country (2019-2024)
7.4 Europe Neurologic Disorders Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Neurologic Disorders Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Neurologic Disorders Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Neurologic Disorders Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Neurologic Disorders Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Neurologic Disorders Therapeutics Market Size (2019-2030)
9.2 Latin America Neurologic Disorders Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Neurologic Disorders Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Neurologic Disorders Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neurologic Disorders Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Neurologic Disorders Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Neurologic Disorders Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Neurologic Disorders Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Biogen Inc.
11.1.1 Biogen Inc. Company Detail
11.1.2 Biogen Inc. Business Overview
11.1.3 Biogen Inc. Neurologic Disorders Therapeutics Introduction
11.1.4 Biogen Inc. Revenue in Neurologic Disorders Therapeutics Business (2019-2024)
11.1.5 Biogen Inc. Recent Development
11.2 F. Hoffmann-La Roche Ltd.
11.2.1 F. Hoffmann-La Roche Ltd. Company Detail
11.2.2 F. Hoffmann-La Roche Ltd. Business Overview
11.2.3 F. Hoffmann-La Roche Ltd. Neurologic Disorders Therapeutics Introduction
11.2.4 F. Hoffmann-La Roche Ltd. Revenue in Neurologic Disorders Therapeutics Business (2019-2024)
11.2.5 F. Hoffmann-La Roche Ltd. Recent Development
11.3 Johnson & Johnson Services Inc.
11.3.1 Johnson & Johnson Services Inc. Company Detail
11.3.2 Johnson & Johnson Services Inc. Business Overview
11.3.3 Johnson & Johnson Services Inc. Neurologic Disorders Therapeutics Introduction
11.3.4 Johnson & Johnson Services Inc. Revenue in Neurologic Disorders Therapeutics Business (2019-2024)
11.3.5 Johnson & Johnson Services Inc. Recent Development
11.4 Novartis AG
11.4.1 Novartis AG Company Detail
11.4.2 Novartis AG Business Overview
11.4.3 Novartis AG Neurologic Disorders Therapeutics Introduction
11.4.4 Novartis AG Revenue in Neurologic Disorders Therapeutics Business (2019-2024)
11.4.5 Novartis AG Recent Development
11.5 Pfizer Inc.
11.5.1 Pfizer Inc. Company Detail
11.5.2 Pfizer Inc. Business Overview
11.5.3 Pfizer Inc. Neurologic Disorders Therapeutics Introduction
11.5.4 Pfizer Inc. Revenue in Neurologic Disorders Therapeutics Business (2019-2024)
11.5.5 Pfizer Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Published By : QY Research

Why ‘The Market Reports’